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Most KRAS G12C mutant non-small cell lung cancer (NSCLC) patients experience clinical 
benefit from selective KRAS G12C inhibition, while patients with colorectal cancer (CRC) 
bearing the same mutation rarely respond.  To investigate the cause of the limited efficacy 
of KRAS G12C inhibitors in CRC, we examined the effects of AMG510 in KRAS G12C 
CRC cell lines. Unlike NSCLC cell lines, KRAS G12C CRC models have high basal 
receptor tyrosine kinase (RTK) activation and are responsive to growth factor stimulation.  
In CRC lines, KRAS G12C inhibition induces higher phospho-ERK rebound than in 
NSCLC cells. Although upstream activation of several RTKs interferes with KRAS G12C 
blockade, we identify EGFR signaling as the dominant mechanism of CRC resistance to 
KRAS G12C inhibitors. The combinatorial targeting of EGFR and KRAS G12C is highly 
effective in CRC cells, patient-derived organoids and xenografts, suggesting a novel 
therapeutic strategy to treat KRAS G12C CRC patients. 
  
Statement of significance 
 
The efficacy of KRAS G12C inhibitors in NSCLC and CRC is lineage-specific. RTK 
dependency and signaling rebound kinetics are responsible for sensitivity or resistance to 
KRAS G12C inhibition in CRC.  EGFR and KRAS G12C should be concomitantly inhibited 




The small GTPase KRAS is mutated and constitutively active in 15% of all human 
tumors(1). This protein acts as a molecular switch, transitioning from an active (GTP-
bound) to an inactive state (GDP-bound). This transition is highly regulated and 
physiologic feedback loops limit the duration of KRAS activation. Guanine exchange 
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factors (GEFs), such as SOS1, and GTPase activating proteins (GAPs), like NF1, directly 
mediate KRAS activation(2, 3). When mutated, KRAS loses the ability to interact with 
GAPs and therefore becomes constitutively activated, driving downstream MAPK and 
PI3K-AKT signaling pathways and enhancing cancer cell proliferation and survival(4). 
Different mutations in KRAS may modify the intrinsic activation (GTP-bound state) of the 
mutant protein and its interaction with downstream effectors, such as RAF proteins(5, 6). 
Moreover, KRAS signaling is also regulated by negative feedback mechanisms through 
the transcriptional induction of protein phosphatases (DUSPs and Sproutys) and 
SPREDs(2). The complexity of the signaling network and the heterogeneous features of 
the multiple KRAS mutant alleles have contributed to the difficulty in developing 
molecularly targeted therapies against mutant KRAS, a target considered undruggable for 
decades.  
 
However, in recent years, the unique characteristics of one of the KRAS mutant alleles, 
KRAS G12C, have been exploited for the design of covalent inhibitors that can specifically 
bind the cysteine on the mutant residue(7). These inhibitors can bind G12C mutant KRAS 
beneath the effector binding switch-II domain when KRAS is in the GDP-bound (inactive) 
state trapping KRAS in its inactive form and taking advantage of the retained, intrinsic 
cycling of the G12C mutant from GTP-bound to GDP-bound states(7, 8). Given this 
particular feature of the KRAS G12C mutant protein, the efficacy of these compounds can 
be increased by concomitant receptor tyrosine kinase (RTK) inhibition that further maintain 
KRAS G12C in a GDP-bound conformation, facilitating the binding of the covalent 
inhibitor(7-9).  
 
Besides RTK inhibition, several other combinatorial strategies have already been 
proposed, with the goal of potentiating the effects of these inhibitors(10-13). Importantly, 
the unique feature of KRAS G12C covalent inhibitors, which only bind the mutant allele, 
renders these drugs a potentially ideal partner for combinatorial strategies, as toxicities 
should be minimized and limited to the combinatorial partner. 
 
Several clinical trials testing the efficacy of KRAS G12C targeted drugs are currently 
ongoing and early results from the first two trials using AMG510 and MRTX849 have 
documented promising outcomes in the clinic. However, clinical studies unexpectedly 
reported that the response rate to these drugs is high in non-small cell lung cancers 
(NSCLC) patients but limited in colorectal cancer (CRC) patients(14, 15).  
 
In this work, we sought to understand the mechanisms underlying this lineage difference. 
We hypothesized that NSCLC bearing KRAS G12C could be intrinsically different from 
KRAS G12C mutant CRC, despite harboring the same oncogenic mutation. We and others 
previously reported that BRAF V600E CRC have limited sensitivity to single agent RAF 
inhibitors, and this is a result of an adaptive response selectively triggered in CRC(16-18).  
 
Therefore, we examined the adaptive response to KRAS G12C inhibition and its kinetics 
in KRAS G12C mutant NSCLC and CRC cell models. We show that KRAS G12C mutant 
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CRCs maintain sensitivity to upstream RTK signaling, particularly EGFR. Using 
biochemical and pharmacological approaches, we show that EGFR reactivation restricts 
the efficacy of KRAS G12C inhibition in CRC.  We find that KRAS G12C and EGFR 
blockade is effective to overcome this adaptive resistance, both in cell lines and in patient-
derived models. These findings have immediate relevance for clinical strategies to 





ERK inhibition is not sustained in CRC cell lines treated with AMG510 
To understand the mechanistic basis for differential clinical responses to treatment with 
the selective KRAS G12C inhibitor AMG510 in CRC and NSCLC, we analyzed the effect 
of this drug in a panel of KRAS G12C mutant cell lines. These included two NSCLC 
(NCIH358 and LU65) and seven CRC cell lines (C106, RW7213, SW837, SNU1411, 
JVE015 and LIM2099). Response to AMG510 was measured in a dose-response 
proliferation assay. Sensitivity to single agent was comparable among the models, 
showing no clear difference between CRC and NSCLC cell lines (Figure 1A). Therefore, 
to explore the quality, duration, and adaptive signaling response to drug treatment, we 
compared the NSCLC cell lines to four CRC models, consisting of two representative 
models with low IC50 to AMG510 (C106, RW7213) and two representatives with high IC50 
values (SW837 and SNU1411). Cells were subjected to increasing concentrations of 
AMG510 for 1 hour and 24 hours (Figure 1B). After one hour of drug treatment, KRAS 
G12C inhibition led to downregulation of phosphorylated ERK in a dose-dependent 
manner in all cell models, regardless of tumor lineage. However, after 24 hours of drug 
exposure, we observed that both NSCLC cell lines further downregulated ERK 
phosphorylation, while all the CRC cell lines showed a rebound in phospho-ERK levels 
(Figure 1C-D). We then examined the impact of AMG510 on the signaling network over 
time in NSCLC and CRC cell lines. At baseline, the CRC cell line C106 expressed lower 
levels of phosphorylated MEK and ERK with similar total protein relative to the NSCLC 
line NCIH358. Treatment with AMG510 decreased levels of active RAS-GTP, but the 
suppression was more pronounced in the NCIH358 compared to C106.  In C106, residual 
phospho-MEK and ERK were measurable already after one hour of treatment while the 
NSCLC cell line (NCIH358) showed signs of rebound in phospho-MEK and phospho-ERK 
only at 72 hours after treatment (Supplementary Figure 1A-B-C). Altogether, these data 
show that MAPK pathway inhibition upon AMG510 treatment is transient and less 
profound in CRC than lung models and suggest that this may be due to greater feedback 
suppression of MAPK signaling in CRC that is then released with KRAS G12C inhibition.  
 
Colorectal cancer cells bearing the KRAS G12C mutation display high basal RTK 
activation 
KRAS mutation acts downstream of RTK signaling and leads to constitutive ERK 
activation, in turn, high ERK levels feedback inhibit receptor signaling(19).  KRAS mutant 
proteins are thought to be constitutively active, therefore it would be expected that KRAS 
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mutant tumors do not rely on RTK activation. To characterize the basal level of RTKs in 
patient tumors we assembled a series of CRC and NSCLC clinical samples carrying the 
KRAS G12C mutation.  We analyzed eight CRC and five NSCLC patient specimens 
(Supplementary table 1), all collected before any targeted therapy treatment, and 
evaluated the expression of 72 different proteins, including RTKs, using an SRM-mass 
spectrometry assay (see methods).  Detectable levels of EGFR, HER2, and MET were 
present in both lineages without clear differences, while HER3 expression was more 
prevalent in CRC patient samples (Figure 2A). We did not detect ALK, ROS1, RET, FGFR, 
or AXL expression in any of the samples.  Two CRC patients and two NSCLC patients 
later went on the phase 1 trial of AMG510 (Supplementary table 1). Despite similar basal 
total RTK levels in the tumors from trial enrolled patients, both NSCLC cases achieved 
clinical benefit, while both CRC patients progressed upon AMG510 treatment. These data 
indicate that even in the presence of KRAS G12C mutation, tumors often express 
upstream RTKs, predominantly consisting of HER family and MET receptors. However, 
the levels of total RTK expression do not appear to underlie lineage specific differential 
response to KRAS G12C inhibition between CRC and NSCLC patients. 
 
While we were able to detect total RTK expression in the clinical samples, we could not 
assess activated RTK levels or evaluate the functional consequences of detectable RTK 
expression in these tumors. To test this, we measured the levels of active RTKs in CRC 
and NSCLC cell lines using phospho-RTK arrays. The NSCLC cell line NCIH358 had no 
detectable basal RTK activation and low levels of the p-EGFR and p-IGF-IR could be 
detected only with signal enhancement through long exposure. In contrast, both CRC cell 
lines, C106 and RW7213, showed a number of detectable phosphorylated RTKs (Figure 
2B). Marked phospho-EGFR signal was present in both CRC models and was 
accompanied by detectable levels of other phosphorylated receptors. Co-
immunoprecipitation assays using cetuximab as a capture antibody confirmed that EGFR 
is bound to the other HER receptors MET and FGFR suggesting hetero-dimerization 
processes (Supplementary Figure 2A-B). Several Ephrin receptors were also found 
activated in CRC cell lines. Interestingly EphR activation has been reported as mechanism 
of resistance to cetuximab in CRC and head and neck squamous cell carcinoma and CRC, 
suggesting that the cross talk between these two classes of RTKs can potentially amplify 
EGFR signaling(20). 
 
We next investigated the functional effect of the high levels of basal RTK activation in the 
CRC cell lines by evaluating the signaling consequences of EGF stimulation over time. At 
baseline, signaling downstream of RAS (phospho-AKT, phospho-MEK, phospho-ERK) 
was lower in the colon cancer cell lines compared to the NSCLC line NCIH358.  EGF 
treatment led to induction of phospho-EGFR in all cell models (Figure 2C). However, 
activation of downstream effectors showed lineage-specific differences. The NSCLC cell 
line NCIH358 did not show any modulation of AKT, MEK or ERK phosphorylation upon 
EGF treatment, suggesting that KRAS G12C does not get (further) activated by EGFR 
stimulation and can sustain downstream signaling without upstream inputs (Figure 2C-D). 
In contrast, in the CRC cell lines C106 and RW7213, downstream effectors followed the 
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same kinetics of EGFR activation, showing that KRAS G12C can be activated by upstream 
signaling components and that basal activation of RAS downstream effectors may be 
lower due to negative feedback loops (Figure 2C-D). Altogether, these data indicate that 
even in the presence of the same KRAS activating mutation, lineage-specific differences 
exist in the degree of RTK activation, contribution of upstream receptors to ERK activation 
(and thus rate of cycling of KRAS between the GTP- and GDP-bound forms), and 
feedback mechanisms that would be released from suppression by selective KRAS 
inhibitors-mediated ERK inhibition. 
 
Cetuximab sensitizes KRAS G12C CRC cell lines to AMG510 and concomitant EGFR 
and KRAS G12C blockade reverts secondary resistance to anti EGFR antibodies  
Based on the high levels of basally active EGFR, the contribution of EGFR to KRAS G12C 
signaling outputs, and the known relevance of EGFR signaling in CRC, we next evaluated 
whether KRAS G12C-EGFR combined inhibition could effectively suppress signaling and 
growth in the CRC models. Biochemical analysis and densitometric quantitation of 
phosphoprotein levels showed that concomitant KRAS G12C and EGFR inhibition, with 
the anti-EGFR antibody cetuximab, led to sustained inhibition of phospho-MEK and 
phospho-ERK, as well as the ERK downstream targets DUSP6 and CyclinD1, indicating 
inhibition of ERK output (Figure 3A and Supplementary Figure 3A-B). CRC cell lines were 
also tested in short-term proliferation assays. ATP content measurement showed that 
concurrent treatment with the EGFR inhibitor cetuximab synergized with AMG510 in all 
the cell lines tested (Figure 3B and Supplementary Figure 4A). Growth suppression was 
durable as similar effects were also seen in long-term proliferation assays stained with 
crystal violet (Figure 3C). 
 
We next sought to determine whether combined KRAS and EGFR inhibition could lead to 
cell death together with cell proliferation arrest. We found that the combination treatment 
induced a pronounced cytotoxic effect, as measured by detection of DNA of cells with 
impaired membrane integrity, in all the models tested and across dose levels of AMG510 
(Figure 3D).  These data indicate that combined KRAS G12C and EGFR inhibition leads 
to increase cell death rate. 
 
To further assess the role of EGFR signaling in AMG510 resistance, we used the KRAS 
wild type, cetuximab sensitive, CRC cell line LIM1215 to generate isogenic models 
carrying the KRAS G12C allele using an AAV mediated knock-in approach(21). As 
expected, all KRAS G12C mutant clones (KI#1, KI#2 and KI#3) showed resistance to 
cetuximab as a single agent (Figure 3E). KRAS G12C mutant clones were more sensitive 
to AMG510 than their wild type counterpart (Figure 3F). The addition of cetuximab in 
combination with KRAS G12C inhibition was synergistic compared to the single agent 
alone (Figure 3G and Supplementary Figure 4B). These results provide further support 
that EGFR and KRAS G12C should be concomitantly inhibited to overcome resistance to 




We and others previously reported that KRAS acquired mutations are responsible for 
secondary resistance to anti-EGFR therapies in CRC(22, 23). We reasoned that KRAS 
inhibitors could have clinical applications in patients who develop KRAS mutations at 
relapse after EGFR blockade. To directly test this possibility, we used a CRC cell line 
(HCA46-R Pmab), in which prolonged treatment with panitumumab lead to the emergence 
of a KRAS G12C allele(24). We examined whether AMG510 could be effective in this 
setting. While single agent AMG510 treatment was partially effective, its combination with 
cetuximab induced both cell proliferation arrest and cell death (Figure 3H-J and 
Supplementary Figure 4C). These data suggest that also in the secondary resistance 
setting CRC cells could retain upstream signaling dependency.  
 
CRC patient-derived models are sensitive to combinatorial EGFR-KRAS G12C 
inhibition 
To test whether and to what extent these findings were applicable to clinically relevant 
models we collected biopsies and exploited established models from CRC patients 
generated in our institutions (Supplementary tables 2-3). 
Taking advantage of our molecularly and therapeutically annotated CRC patient-derived 
bio-bank (25-27), in a cohort of more than one hundred patient-derived organoids (PDO), 
we selected three different KRAS G12C mutant PDOs and one KRAS G12D mutant PDO 
(as negative control) and tested the effects of single agents AMG510, cetuximab and their 
combination. 
In the KRAS G12C PDOs, single agent AMG510 or cetuximab did not or poorly inhibited 
growth, while the combination suppressed proliferation with high synergy scores (Figure 
4A-B-C).  
In parallel, we generated patient-derived xenografts (PDXs) from two patients with KRAS 
G12C mutant CRC and tested AMG510 and cetuximab as single agents and their 
combination in vivo. Both models exhibited slowed but persistent growth when mice were 
treated with either cetuximab or AMG510 single agent treatment. Combination treatment 
induced massive or even complete tumor shrinkage in the treated animals (Figure 4D-E).  
No tumor was visible after 10 weeks of treatment and no samples could be collected at 
the end of the PDX experiment (Figure 4E). Interestingly, IHC staining for the proliferation 
marker Ki67 was highly positive in tumor samples derived from vehicle, cetuximab and 
AMG510 treated arms (Ki67 IHC intensity of 97% with no necrosis in vehicle treated mice, 
92% with necrosis in cetuximab treated mice, and 83% with necrosis in AMG510 treated 
mice) but strong phospho-ERK staining was observed only in the AMG510 treated 
samples, suggesting that strong MAPK pathway rebound occurs in patient-derived 




Recent clinical data have shown promising activity of agents targeting mutant (G12C) 
KRAS, a heretofore-undruggable target. These trials, however, show substantial 




We found that KRAS G12C inhibitors produce less profound and more transient inhibition 
of KRAS downstream signaling in CRC versus NSCLC models. Our data indicate that, 
despite harboring the same mutation, there are intrinsic differences in signaling between 
CRC and NSCLC. Our data suggest that in CRC the combination of (1) signaling rebound 
upon KRAS G12C inhibition, (2) the higher extent of RTK activation and (3) the stronger 
response to EGFR direct stimulation can be used to define the intrinsic dependency of 
bowel tumors on EGFR-MAPK pathway. These results, together with the emerging clinical 
experience with single agent KRAS G12C inhibitors, indicate that combinatorial treatment 
is necessary to effectively treat KRAS G12C mutant CRC.  
 
This is, to our knowledge, the first study aimed at specifically characterizing the effects of 
KRAS G12C inhibition in CRC. Indeed, the main goal of this work was to understand and 
exploit CRC lineage-specific features to develop more effective pharmacological 
strategies.  
 
It is known that RTK inhibition in NSCLC preclinical models can potentiate KRAS G12C 
covalent inhibitors, by slowing down exchange factors favoring a GDP-bound status of 
KRAS(8). However this combinatorial strategy is considered only marginal in this setting 
as other combinatorial partners including PI3K, mTOR, and Aurora Kinase inhibitors have 
been shown to have higher efficacy than EGFR inhibition in combination with KRAS G12C 
inhibition in lung cancer(10, 12, 13).  
 
We found that expression of EGFR and its dimerization partners is common in KRAS 
G12C CRC and NSCLC clinical samples.  Basal EGFR expression, as measured by 
immunohistochemistry or mass spectrometry(28, 29), has not been associated with EGFR 
inhibitor sensitivity in CRC, and indeed we find no clear difference between receptor 
expression levels by lineage or in the subset of CRC and NSCLC patients treated with 
AMG510.  In cell line models, however, we are able to assess activated RTK levels and 
we find that the degree of this dependency on RTK signaling across KRAS G12C mutant 
tumors can be very different. Specifically, we show that KRAS G12C mutant CRC cell 
lines still retain their dependency on EGFR for downstream signaling. 
 
The clinical and signaling effects of AMG510 in CRC is reminiscent of the clinical 
experience in BRAF V600E CRC, where the concomitant inhibition of upstream signaling 
reactivation results in improved clinical efficacy (30), which has led to the recent FDA 
approval of the BRAF inhibitor encorafenib in combination with cetuximab (BEACON 
CRC; NCT02928224).   
Clinical trials results have shown limited efficacy of KRAS G12C covalent inhibitors in 
CRC; only one CRC patient treated with MRTX849 had a 47% tumor reduction by RECIST 
criteria(15). Our results show that in CRC cell models and in PDX, treatment with AMG510 
single agent induces strong reactivation of MAPK pathway. These data indicate that even 
in the best scenario, upfront combination treatment is the best option for KRAS G12C 
mutant CRC patients, as this approach would enhance the efficacy of KRAS G12C 




We showed that KRAS G12C mutant CRC still retains EGFR-MAPK dependency, as 
demonstrated by the signaling rebound upon KRAS G12C inhibition, the more pronounced 
activation of RTKs and the high response to EGFR direct stimulation. We can speculate 
that also other KRAS mutant alleles in CRC could retain these characteristics suggesting 
that also other KRAS mutant CRC could potentially benefit from EGFR-based 
combinations. Therefore, direct or indirect KRAS blockade-based combinations could be 
considered as an option in these specific settings.  
 
Combined inhibition of KRAS G12C with SHP2, a phosphatase that serves as a common 
mediator of RTK signaling to RAS(31), has been proposed as another combination to 
overcome the feedback reactivation in KRAS G12C tumors(32).  
Available clinical data with SHP2 inhibitors is currently limited and it is not yet known if 
these inhibitors can be administered to patients in sufficient doses to effectively inhibit 
RTK signaling. Further, preclinical models suggest growth suppression but not complete 
tumor regression with SHP2 and KRAS G12C inhibitors, in contrast to the complete, 
durable tumor inhibition achieved in a patient-derived xenograft treated with EGFR and 
KRAS G12C inhibitors. 
 
Since RTK signaling in CRC is mostly dominated by wild-type EGFR, we propose to 
combine KRAS G12C inhibitors with anti-EGFR monoclonal antibodies to block receptor 
signaling rather than inhibiting EGFR kinase activity. Moreover, the differential activity of 
EGFR inhibitors in CRC versus NSCLC further indicate signaling differences in these two 
lineages(33). The anti-EGFR antibodies cetuximab and panitumumab are approved for 
the treatment of RAS/RAF wild type CRC(34, 35), while EGFR tyrosine kinase inhibitors 
(TKI) are approved for the treatment of EGFR mutant lung cancer(36). EGFR-targeting 
TKI have not been effective in CRC(37), probably because EGFR genetic alterations are 
rare in CRC and these drugs are more efficient in EGFR-mutant setting. As release of wild 
type receptor signaling from feedback inhibition is thought to mediate adaptive resistance 
to targeted therapies, the role of wild type EGFR in activating signaling in CRC could 
render CRCs more sensitive to this feedback release than NSCLC. 
 
Taken together, our results demonstrate that biochemical characterization of response to 
KRAS G12C inhibitors in CRC provides a mechanistic explanation for their limited activity 
in the clinic and, at the same time, provides a strong rationale to combine EGFR blockade 





Cell lines and Compounds 
The cell lines NCIH358, LU65, SNU1411, JVE015, LIM2099, LIM1215, LIM1215 KRAS 
G12C KI cell lines and RW7213 were cultured in RPMI (Lonza). C106 cell line was cultured 
in Iscove’s modified medium (Lonza).  SW837 cell line was cultured in DMEM/F12 
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(Lonza). HCA46-R Pmab cell line was cultured in DMEM (Lonza). Each media was 
supplemented with 10% FBS, 2mM L-glutamine, 100U/ml penicillin and 100mg/mL 
streptomycin. SW837 and NCIH358 cell lines were purchased from ATCC; C106 and 
HCA46 cells were purchased from ECACC, SNU1411 cells were purchased from KCLB; 
LU65 were purchased from AcceGen Biotech; LIM2099, LIM1215 were kindly provided 
from Dr. Whitehead (Australia); JVE015 were provided from Prof. Tom Van Wezel 
(LUMC); RW7213 were provided by Dr. Diego Arando. 
All the cell lines were determined to be mycoplasma free using the Venor® GeM Classic 
kit (Minerva biolabs) and tested by Short Tandem Repeats profiling at 10 different loci. 
AMG510 was purchased from ChemGood (C-1499) and cetuximab was either gifted from 
Merck Serono under an academic material transfer agreement or purchased from the 
Pharmacy at Memorial Sloan Kettering Cancer Center. 
 
Patient-Derived Organoids  
All the procedures performed with patient specimens were conducted under the approval 
of the local Ethical Committee of the institutions, after the written consent of the patients. 
CRC1589, CRC1360 and CRC0051 patient-derived organoids (PDOs) were derived from 
PDXs established from three distinct KRAS G12C CRC patients while IRCC107A patient-
derived organoid (PDO) was established directly from tissue biopsy obtained at the time 
of surgery.To generate PDX-derived organoids, PDX samples were first dissociated 
mechanically with gentle MACS Dissociator (Milteny Biotec) and then underwent to 
enzymatically digestion of extracellular matrix using Human Tumor Dissociation Kit 
(Miltenyi Biotec). The derived single cell suspension was centrifuged at 400g for 5 minutes 
and the resuspendend in the organoids’ Basal medium. Cell suspension was filtered with 
70-uM cell strainer in order to avoid cell clustering formation. The flow-through was 
centrifuged and the pellet was resuspended in Matrigel (Corning) and dispensed as 100ul 
droplet in the center of 37°C prewarmed 12-well plate. After an incubation of 15 minutes 
at 37°C for matrigel solidification, organoids were added with ENAS medium and 
incubated at 5%CO2 and 37°C.  ENAS medium is refreshed twice per week. 
Differently, to generate PDOs directly from patient tissue biopsy, tumor tissue was first 
smashed in small pieces and incubated in PBS with collagenase A (0.5 mg/mL; Roche), 
hyaluronidase (20 mg/mL; Sigma), and 10 mmol/L ROCK inhibitor for 30 minutes at 37°C 
with shaking. After incubation, 5% FBS was added and the mixture was centrifuged at 400 
g for 5 minutes. The pellet was washed three times in PBS to remove debris and 
collagenase. At the end of the washing phase, the pellet was resuspended in Matrigel 
(Corning) and 50 uL of organoids-Matrigel suspension were dispensed into the center of 
each well of a 37°C prewarmed 24-well plate. Different densities of tumor cells were plated 
and left to solidify for 10 to 30 minutes at 37°C before ENAS medium was added and the 
cells were incubated at 37°C, 5% CO2. Fresh medium was replaced every 2 to 3 days. 
Outgrowing organoids were passaged every 10 to 15 days after mechanical and 
enzymatic disruption. Organoid drug treatment was performed in each organoid-specific 
culture medium at 37°C and 5% CO2. 
The organoid Basal Medium is composed of Advanced DMEM/F12 medium (Thermo 
Fisher) containing 100 U/mL penicillin, 100µg/mL streptomycin, 2 mM GlutaMAX (Gibco), 
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10 mM Hepes, 50 ug/mL Primocin, (Invitrogen). ENAS medium is prepared by adding 
1 × B27 supplement (Invitrogen), 1 × N2 supplement (Invitrogen), 1.25 mM N-acetyl-
cysteine (Sigma Aldrich), 10 mM Nicotinamide (Sigma Aldrich), 10 nM gastrin (Sigma), 
50 ng/mL recombinant mouse EGF (Life Technologies), 100 ng/mL Noggin (PeproTech), 
500 nM TGFb type I receptor inhibitor A83-01 (Tocris) and 10 μM p38 MAPK inhibitor 
SB202190 (Sigma Aldrich) to the organoid Basal Medium. 
 
Antibodies and Western blotting 
After seeding and drug treatments, cells were washed with cold PBS and lysed in RIPA 
buffer (Pierce #89901) plus phosphatase and protease inhibitors (Thermo Scientific 
#1861277, #1861278). Lysates were cleared by centrifugation at 14000rpm at 4°C and 
quantified using BCA method (Pierce #23224). 
Samples were prepared using LDS+Reducing agent Novex buffers (Invitrogen #NP0008, 
#NP0009). 10 to 20μg of lysates were loaded and run on NuPageTM 4-12% Bis-Tris gels 
(ThermoFisher #NP0321BOX) followed by transfer to nitrocellulose membranes (Biorad 
#1620233). Membranes were incubated over night with the indicated antibodies, washed 
and incubated again for 45 minutes with anti-rabbit or anti-mouse secondary antibodies. 
Detection was performed using Immobilion Western (Millipore #WBKLS0500).  
Primary antibodies were obtained from Cell Signaling Technology and were used at a 
concentration of 1:1000:  p-Akt S473 (#9271), p-MEK1/2 S217/221 (#9154), p-p44/42 
MAPK T202/204 (#9101), Total MEK1/2 (#9122), Total ERK1/2 (#9102), Total AKT 
(#9272), Total EGFR (#2232S), phospho-EGFR Tyr1068 (#3777S) and Vinculin 
(#13901S). DUSP6 antibody was purchased from Abcam (#ab54940) and used at 1:500 
dilution. CyclinD1 antibody was purchased from Santa Cruz (#sc-718) and used at 1:1000 
dilution. Densitometry analyses were performed using ImageJ software. 
 
EGFR Immunoprecipitation  
For Immunoprecipitation (IP) assays, cells were seeded and starved for 24h and then 
stimulated with 20% FBS for 10 minutes. Cells were then washed in cold PBS and lysed 
using NP-40 buffer (150 mM NaCl, 10 mM Tris pH 8, 1% NP-40, 10% glycerol). 20 μg of 
proteins were used as total lysates. 1500μg of protein lysates were incubated rotating at 
4°C for 1,5 hours in the presence of 10 μg/mL cetuximab, Agarose protein G beads 
(Invitrogen #15920-010). Beads were centrifuged at 3000 rpm for 1 min and supernatant 
was removed. Similarly, beads were washed three times using NP-40 buffer and once 
using nuclease-free sterile water. Finally, immunoprecipitates were eluted using 1X 
sample buffer (NuPAGE™ LDS Sample Buffer, Thermo Fisher Scientific #NP0008 and 
NuPAGE Sample Reducing Agent, Thermo Fisher Scientific #NP0009) at 95°C for 5 min 
 
RAS-GTP pull-down assay 
RAS-GTP pull –down assay was performed according to manufacturer’s protocol (Thermo 
Scientific #16117). Briefly, 500μg of lysates were loaded into columns together with 
agarose beads and RAS-RBD bait and incubated for 1 hour at 4°C. After the incubation, 
beads were washed three times and resuspended in LDS+Reducing agent Novex buffers 
(Invitrogen #NP0008, #NP0009). A fraction of lysates was used to measure total RAS 
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amount. Pull-Down and total lysates were subjected to western blotting procedure as 
described above. The kit provided primary antibody against pan-RAS. 
 
Phospho-RTK array 
Human Phospho-RTK arrays (R&D Systems, ARY001B) were used to detect activated 
RTKs according to manufacturer’s instructions. Cells were washed with cold PBS and 
lysed using the provided lysis buffer plus phosphatase and protease inhibitors. 200 μg 
lysates were incubated on membranes overnight. Membranes were subsequently washed 
and exposed to chemiluminescent reagent. 
 
Mass Spectrometry 
Selected reaction monitoring-mass spectrometry (SRM-MS) of 72 biomarkers of the tissue 
sections from FFPE blocks was conducted as previously described(38, 39). Briefly, two 
tissue section sections (10µM each) from FFPE blocks were placed on DIRECTOR slides, 
deparaffinized, and stained with hematoxylin. Tumor areas were marked by board-certified 
pathologist, then was micro-dissected and solubilized to tryptic fragments as per 
manufacturer instructions (Expression Pathology, Rockville, MD). Protein concentration of 
the tryptic peptides was calculated using microBCA. Stable heavy isotope-labeled internal 
standard peptides for 72 biomarkers was added to the solution and injected into the mass 
spectrometer (TSQ Quantiva, ThermoFisher Scientific, San Jose, CA). On-column 
injection resulted in 5fmol of isotopically labeled internal standard peptide and 1µg of total 
tumor protein. Data analysis of the 72 biomarkers was conducted using Pinnacle software 
(Optys Tech, Boston, MA). All patients whose tumors were analyzed signed written 
consent for molecular profiling of their tumors (IRB 12-245) and approval was obtained for 
the mass spectrometry assay (appendix C). 
 
Drug proliferation assays 
For short-term proliferation assays, 2,000 cells were seeded in 96-well culture plates in 
medium containing 10% FBS. After 24 hours, serial dilutions of AMG510 (alone or in 
combination with Cetuximab) were added to cell in 10% FBS medium (ratio 1:1). Cell 
viability was determined at day 5 after the start of the treatment by measuring ATP content 
using Cell Titer-Glo® Luminescent Cell Viability assay (Promega). DMSO-only treated 
cells were used as control. Excess over the Bliss (Bliss score) was calculated using effect 
of the combo (observed) versus what was predicted/expected based on the effect of each 
single agent expressed as percentage. Negative values on values close to zero show 
no/very little synergy. Higher percentages indicate higher synergy. 
For long-term proliferation assays, cells were seeded (5000 per well for SNU1411, SW837 
and HCA46R, 80000 cells per well for RW7213) in 24-well plates or in 6-well plates (C106 
80000 cells per well) in 10% FBS medium. The following day, plates were treated with 
different concentrations of drugs as indicated. Cells were fixed with 4% paraformaldehyde 
and stained with 10% Crystal Violet in a Methanol/Water solution (Sigma Aldrich) 9 to 13 
days after the start of treatment, according to the confluence reached by the untreated 
control. Every 7 days, media and drug were refreshed. In all the experiments, plates were 
incubated at 37°C in 5% CO2. 
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Short-term assays were performed at least three times. All long-term assays were 
performed independently at least three times. Analyses and graphs were performed with 
GraphPad Prism Software using the function log (inhibitor) versus response-variable slope 
(4 parameters).  
 
Drug cytotoxicity assay 
For short term cytotoxicity assay, 2,000 cell/well were seeded in 96-well plates and treated 
after 24 hours with AMG510 alone or in combination with cetuximab as indicated. After 5 
days from the start of treatment, cell cytotoxicity was determined measuring the 
fluorescence of death cells using CellTox Green cytotoxicity assay (Promega), according 
to the kit instruction. The CellTox green results were normalized on results of Cell Titer-
Glo® Luminescent Cell Viability assay conducted on the same plates. In all the 
experiments, plates were incubated at 37°C in 5% CO2. All assays were performed 
independently at least three times 
 
In vivo studies 
The CLR113 PDX was derived from a liver metastasis under written consensus. Tumor 
tissue was transplanted orthotopically into NSG mice to establish the PDX (IRB protocols 
06-107, 14-091). Once a tumor became visible in the first mouse, it was transplanted and 
expanded to other animals. Tumor tissue was implanted subcutaneously in the flank of 4–
6-week-old NSG female mice and treatment of the mice began when tumor reached 
approximately 100mm3 in size. Mice were randomized (n = 5 mice per group) to receive 
drug treatments or vehicle as control. Studies were performed in compliance with 
institutional guidelines under an IACUC approved protocol. The animals were immediately 
euthanized as soon as the tumors reached the IACUC set limitations. 
The CRC0051 PDX was derived from a colorectal cancer patient metastasis, under written 
consensus. Patient tissue was transplanted into a NOD-SCID mice to establish PDX and 
then transplanted and expanded to other animals. Tumor was implanted subcutaneously 
in the flank of 11-13-week-old NODSCID mice and treatment of the mice began when 
tumor reached approximately 250 mm3. Mice were randomized (n=7 per arm) and 
received drug treatment or vehicle control. 
AMG 510 was given 100mg/kg daily by gavage. Cetuximab was administered 50mg/kg 
twice a week, by intra-peritoneal injections. 
The entire experiment was performed in compliance with institutional guidelines under the 
Ethical committee of Candiolo Cancer Institute consensus and under the Italian Ministry 
of Health approved protocol. The animals were sacrificed on the base of the rules defined 
in the approved protocol. 
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Figure 1: Response to KRAS G12C inhibition in CRC cell lines. (A) Short term proliferation 
assay of CRC cell lines (shades of red) and NSCLC cell lines (shades of blue). Cells were 
treated for 120 hours with increasing concentration of AMG510 and then ATP content was 
measured using CellTiterGlo. Data represents the average and standard deviation of 3 
biological replicates. (B) Western blot analysis of ERK activation upon AMG510 dose-
response treatment after 1 hour and 24 hours treatment. Vinculin is used as loading control. 
(C) Densitometry analysis of CRC cell lines in western blot in (B). p-ERK values are normalized 
on both total ERK and Vinculin and on DMSO control. (D) Densitometry analysis of NSCLC 
cell lines western blot in (B). p-ERK values are normalized on both total ERK and Vinculin and 
on DMSO control.   
 
Figure 2: RTK component and responsiveness in CRC cell lines. (A) Mass spectrometry 
analysis of RTK in CRC and NSCLC patients-derived biopsies. (B) Phospho-RTK array of 
NCIH358 (NSCLC), C106 and RW7213 (CRC) cell lines. Cell were FBS starved for 24h and 
stimulated with 20% FBS for ten minutes before harvesting. (C) Western blot analysis of KRAS 
downstream effectors in NCIH358 (NSCLC), C106 and RW7213 (CRC) cell lines upon time 
course EGF treatment. Vinculin is used as loading control. (D) Densitometry analysis of p-
AKT, p-MEK and p-ERK of western blot in (C). Phospho-proteins values are normalized on 
total proteins and Vinculin and on not treated (NT) control.   
 
Figure 3: EGFR inhibition sensitizes CRC cell lines to AMG510. (A) Western blot analysis 
of cetuximab plus AMG510 combinatorial treatment in time course in C106, RW7213, 
SNU1411 and SW837 CRC cell lines. RAS-GTP pull down assay is included, and Vinculin is 
used as loading control. (B) Short-term proliferation assay of C106, RW7213, SNU1411 and 
SW837 treated with increasing concentration of AMG510 with or without 50ug/mL cetuximab. 
First data points of the combination curves represent the response to cetuximab alone. Cells 
were treated for 120 hours with increasing concentration of AMG510 and then ATP content 
was measured using CellTiterGlo. Data represents the average and standard deviation of 3 
biological replicates. The AMG510 single agent curves used in this graph, are the same used 
in fig 1A. (C) Long-term drug screening proliferation assay of C106, RW7213, SNU1411 and 
SW837 treated with increasing concentration of AMG510 with or without 50μg/mL cetuximab. 
Cetuximab only treated cells are shown in the first lower circles. Cells were treated for 9 to 13 
days according to the time when untreated controls reached confluence. (D) CellTox assay of 
C106, RW7213, SNU1411 and SW837 treated with increasing concentration of AMG510 with 
or without 50μg/mL cetuximab. Cetuximab only treated cells are shown as the first red bar at 
0μM AMG510. Cells were treated for 120 hours. Data represents the average and standard 
deviation of 3 biological replicates. Statistical significance was calculated using one-way 
ANOVA with Bonferroni’s correction. Asterisks indicates *=p<0.05, **=p<0.01, ***=p<0.001, 
****=p<0.0001, n.s.= not significant. (E) LIM1215 KRAS G12C Knock-In (KI) clones response 
to cetuximab; LIM1215 parental cells were included as control. (F) LIM1215 KRAS G12C KI 
clones response to AMG510 in short-term proliferation assay. Cells were treated for 120 hours 
with increasing concentration of AMG510 and then ATP content was measured using 
CellTiterGlo. Data represents the average and standard deviation of 3 biological replicates. 
(G) LIM1215 KRAS G12C KI clones response to AMG510+cetuximab in short-term 
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proliferation assay. First data points of the combination curves represent the response to 
cetuximab alone. Cells were treated for 120 hours with increasing concentration of AMG510 
and then ATP content was measured using CellTiterGlo. Data represents the average and 
standard deviation of 3 biological replicates. (H) HCA46-R Pmab cell line response to 
AMG510+cetuximab in short-term proliferation assay. First data point of the combination curve 
represents the response to cetuximab alone. Cells were treated for 120 hours with increasing 
concentration of AMG510 and then ATP content was measured using CellTiterGlo. Data 
represents the average and standard deviation of 3 biological replicates. (I) Long-term drug 
screening proliferation assay of HCA46-R Panitumumab treated with increasing concentration 
of AMG510 with or without 50ug/mL cetuximab. Cetuximab only treated cells are shown in the 
first lower circles. (J) CellTox assay of HCA46-R Pmab treated with increasing concentration 
of AMG510 with or without 50ug/mL cetuximab. Cetuximab only treated cells are shown as 
the first red bar at 0μM AMG510.Data represents the average and standard deviation of 3 
biological replicates. Statistical significance was calculated using one-way ANOVA with 
Bonferroni’s correction. Asterisks indicates *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001, 
n.s.= not significant. 
 
Figure 4: AMG510+cetuximab combination is effective in KRAS G12C mutant patient-
derived models. (A) Bright-field microscopy images of patient-derived organoid (PDO) treated 
with vehicle, AMG510, cetuximab and the combination 7 days after treatment. (B) ATP content 
quantification with CellTiterGlo assay. (C) Synergy score. Heatmap of excess over the Bliss 
(Bliss score) for AMG510-Cetuximab combination. (D) CRC0051 KRAS G12C mutant CRC 
patient-derived xenografts (PDXs) were treated with vehicle alone, AMG510 100mg/kg oral 
BID, cetuximab 50 mg/kg intraperitoneal twice a week (BIW), or the combination of the 2 drugs 
at the same doses. Error bars represent SEM (5 animals per group) (E) CLR113a KRAS G12C 
mutant CRC patient-derived xenografts (PDXs) were treated with vehicle alone, AMG510 
100mg/kg oral BID, cetuximab 50 mg/kg intraperitoneal twice a week (BIW), or the combination 
of the 2 drugs at the same doses. Error bars represent SEM (5 animals per group). (F) Ki67 
and phospho-ERK immunohistochemical staining of the CLR113a PDX samples collected at 
the end of treatment from vehicle, cetuximab and AMG510 treated arms. Ki67 IHC intensity 
of 97% with no necrosis in vehicle treated mice, 92% with necrosis in cetuximab treated 
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